Floatz logo

Doxycycline

Metabolic Disease

National Human Genome Research Institute (NHGRI)Small moleculePhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Metabolic Disease cohort.

Asset / SponsorPhaseRating
Tirzepatide
Washington University School of Medicine
Phase 4BBB
MIDAZOLAM
Baskent University
Phase 4BB
GLUCOSE, ANHYDROUS
University Hospital Schleswig-Holstein
Phase 4BB
Terazosin
I.R.C.C.S. Fondazione Santa Lucia
Phase 4BB
PROPOFOL
Baskent University
Phase 4BB

View all 32 →

Same molecule, other indications

Doxycycline is also rated in:

lymphangioleiomyomatosisDormant
BB
Indicative ·
64 / 100
View asset →
tuberous sclerosisDormant
BB
Indicative ·
64 / 100
View asset →
Chronic Pelvic Pain SyndromeDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →